189 related articles for article (PubMed ID: 9454742)
1. Factor V Cambridge: a new mutation (Arg306-->Thr) associated with resistance to activated protein C.
Williamson D; Brown K; Luddington R; Baglin C; Baglin T
Blood; 1998 Feb; 91(4):1140-4. PubMed ID: 9454742
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the molecular defect in factor VR506Q.
Kalafatis M; Bertina RM; Rand MD; Mann KG
J Biol Chem; 1995 Feb; 270(8):4053-7. PubMed ID: 7876154
[TBL] [Abstract][Full Text] [Related]
3. The mechanism of inactivation of human platelet factor Va from normal and activated protein C-resistant individuals.
Camire RM; Kalafatis M; Cushman M; Tracy RP; Mann KG; Tracy PB
J Biol Chem; 1995 Sep; 270(35):20794-800. PubMed ID: 7657663
[TBL] [Abstract][Full Text] [Related]
4. Proteolytic events that regulate factor V activity in whole plasma from normal and activated protein C (APC)-resistant individuals during clotting: an insight into the APC-resistance assay.
Kalafatis M; Haley PE; Lu D; Bertina RM; Long GL; Mann KG
Blood; 1996 Jun; 87(11):4695-707. PubMed ID: 8639839
[TBL] [Abstract][Full Text] [Related]
5. Biochemical prototype for familial thrombosis. A study combining a functional protein C mutation and factor V Leiden.
Kalafatis M; Lu D; Bertina RM; Long GL; Mann KG
Arterioscler Thromb Vasc Biol; 1995 Dec; 15(12):2181-7. PubMed ID: 7489240
[TBL] [Abstract][Full Text] [Related]
6. Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients.
Födinger M; Mannhalter C; Pabinger I; Koizar D; Rintelen C; Hörl WH; Sunder-Plassmann G
Nephrol Dial Transplant; 1996 Apr; 11(4):668-72. PubMed ID: 8671856
[TBL] [Abstract][Full Text] [Related]
7. Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Japanese patients with various forms of thrombosis, and normal individuals.
Zama T; Murata M; Ono F; Watanabe K; Watanabe R; Moriki T; Yokoyama K; Tokuhira M; Ikeda Y
Int J Hematol; 1996 Dec; 65(1):71-8. PubMed ID: 8990627
[TBL] [Abstract][Full Text] [Related]
8. The mechanism of inactivation of human factor V and human factor Va by activated protein C.
Kalafatis M; Rand MD; Mann KG
J Biol Chem; 1994 Dec; 269(50):31869-80. PubMed ID: 7989361
[TBL] [Abstract][Full Text] [Related]
9. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C.
Zöller B; Svensson PJ; He X; Dahlbäck B
J Clin Invest; 1994 Dec; 94(6):2521-4. PubMed ID: 7989612
[TBL] [Abstract][Full Text] [Related]
10. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
Simioni P; Scudeller A; Radossi P; Gavasso S; Girolami B; Tormene D; Girolami A
Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401
[TBL] [Abstract][Full Text] [Related]
11. The activated protein C (APC)-resistant phenotype of APC cleavage site mutants of recombinant factor V in a reconstituted plasma model.
van der Neut Kolfschoten M; Dirven RJ; Tans G; Rosing J; Vos HL; Bertina RM
Blood Coagul Fibrinolysis; 2002 Apr; 13(3):207-15. PubMed ID: 11943934
[TBL] [Abstract][Full Text] [Related]
12. Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V.
Heeb MJ; Kojima Y; Greengard JS; Griffin JH
Blood; 1995 Jun; 85(12):3405-11. PubMed ID: 7780127
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene.
Aparicio C; Dahlbäck B
Biochem J; 1996 Jan; 313 ( Pt 2)(Pt 2):467-72. PubMed ID: 8573079
[TBL] [Abstract][Full Text] [Related]
14. Activated protein C resistance: molecular mechanisms.
Griffin JH; Heeb MJ; Kojima Y; Fernández JA; Kojima K; Hackeng TM; Greengard JS
Thromb Haemost; 1995 Jul; 74(1):444-8. PubMed ID: 8578503
[TBL] [Abstract][Full Text] [Related]
15. The effect of Arg306-->Ala and Arg506-->Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S.
Egan JO; Kalafatis M; Mann KG
Protein Sci; 1997 Sep; 6(9):2016-27. PubMed ID: 9300501
[TBL] [Abstract][Full Text] [Related]
16. Factor V Arg306-->Thr (factor V Cambridge) and factor V Arg306-->Gly mutations in venous thrombotic disease.
Franco RF; Maffei FH; Lourenço D; Morelli V; Thomazini IA; Piccinato CE; Tavella MH; Zago MA
Br J Haematol; 1998 Dec; 103(3):888-90. PubMed ID: 9858251
[TBL] [Abstract][Full Text] [Related]
17. Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Korean patients with deep vein thrombosis.
Kim TW; Kim WK; Lee JH; Kim SB; Kim SW; Suh C; Lee KH; Lee JS; Seo EJ; Chi HS; Kim SH
J Korean Med Sci; 1998 Dec; 13(6):587-90. PubMed ID: 9886165
[TBL] [Abstract][Full Text] [Related]
18. Factor V Arg306 --> Gly mutation is not associated with activated protein C resistance and is rare in Taiwanese Chinese.
Shen MC; Lin JS; Tsay W
Thromb Haemost; 2001 Feb; 85(2):270-3. PubMed ID: 11246546
[TBL] [Abstract][Full Text] [Related]
19. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C.
Nicolaes GA; Tans G; Thomassen MC; Hemker HC; Pabinger I; Varadi K; Schwarz HP; Rosing J
J Biol Chem; 1995 Sep; 270(36):21158-66. PubMed ID: 7673148
[TBL] [Abstract][Full Text] [Related]
20. Functional characterization of recombinant FV Hong Kong and FV Cambridge.
Norstrøm E; Thorelli E; Dahlbäck B
Blood; 2002 Jul; 100(2):524-30. PubMed ID: 12091344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
